The Library
Treatment & Research reports
122 reports, newest first · page 1 of 5
2026
- A Mesothelioma Drug Attacks the Tumor's Own Stress Defenses. Here's What Its First Trial Actually Found
- Alintegimod (7HP349) Trial Adds a Mesothelioma Cohort
- Italian Imaging-Meso Study Maps the Mesothelioma Immune Map
- MDNA11 IL-2 Superkine Trial Includes Pleural Mesothelioma
- Rina-S Trial Adds Mesothelioma to Its Tumor Cohorts
- TNG462 Trial: PRMT5 Inhibitor for MTAP-Deleted Mesothelioma
- STEALTH-001 Trial Tests VET3-TGI in Solid Tumors
- VT3989 TEAD Inhibitor Trial Opens to Mesothelioma Patients
- The NCI's BAP1 Mesothelioma Registry Aims to Enroll 1,000
- South African Asbestos Miners Face Higher Mortality
- 3D Mesothelioma Spheroids Reveal Why Chemo Often Fails
- Mesothelioma Prognosis: ECOG Score Spans 4 to 14 Months
- HIPEC and Cytoreductive Surgery for Peritoneal Mesothelioma
- How to Find and Join a Mesothelioma Trial
- First-Line Mesothelioma Treatment: 18.1 vs. 14.1 Months
- Second-Line Mesothelioma Treatment: What Comes Next
- Mesothelioma Survival Rates by Stage and Histology
- Pleurectomy/Decortication vs Extrapleural Pneumonectomy
- Stage 1 Pleural Mesothelioma: When Surgery Is an Option
- Stage 2 Pleural Mesothelioma: The Borderline-Operable Case
- Stage 3 Pleural Mesothelioma: When Surgery Isn't an Option
- Mesothelioma Chest Pain: What Makes It Different
- Mesothelioma Early Warning Signs After Asbestos Exposure
- The Mesothelioma Symptom Timeline
- Pleural Effusion in Mesothelioma: Drainage and Recurrence
- Stage 4 Mesothelioma: What to Expect
- Two Chemo-Combo Trials, Two Very Different Signals
- FDA Grants Orphan Drug Status to Orion's ODM-212
- V Foundation Grants $1 Million for BAP1 Mesothelioma Study
- Louisiana Mesothelioma by the Numbers